Search Results

In 2010, the U.S. Food and Drug Administration (FDA) approved Actemra (tocilizumab) to treat symptoms of rheumatoid arthritis, a condition that affects more than 1.5 million Americans. Upon its approval, the drug showed fewer initial side effects than other treatments—a factor that encouraged doctors to prescribe the drug to their patients. In fact, gross sales for Actemra totaled $1.7 billion in 2016, and (more...)